The FDA just announced it approved the cell therapy Omisirge from Gamida Cell for severe aplastic anemia (SAA). This is the first cell therapy approved for SAA. SAA is a rare, life-threatening blood disorder. It is often treated with hematopoietic stem cell transplants or immunosuppression. There’s a major autoimmune component to the condition. The FDA […]
The post Gamida Cell’s Omisirge for SAA gets OK on limited data; more low-data FDA approvals likely to come appeared first on The Niche.